PD-1 therapy represses IL-10 expression in TI B cells from patients with HCC, suggesting that PD-1 therapy can enhance antitumor immunity by impairing the TI PD-1+ B cell suppressive capacity (Xiao et al., 2016) (Table 2). Here, PDCD1 is linked to hepatocellular carcinoma.